Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Empathy training for cancer doctors aims to erase lung cancer stigma

NCT ID NCT05456841

Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests whether a special training program can help cancer doctors communicate more empathetically with lung cancer patients. Many lung cancer patients feel judged or stigmatized during medical visits, which can harm their well-being and care. The training teaches doctors skills to reduce that stigma. Over 1,200 healthcare providers from across the U.S. will participate, and researchers will measure if doctors actually use these new skills in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,232 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Site Eligibility * Employs at least 15 FTE OCPs (i.e., oncologists, nurse practitioners and physician assistants) as per self report * Reports a clinic volume of at least 20 new lung cancer patients per month as per self report OCP Participant Eligibility * OCPs who are thoracic oncology physicians (radiologists, medical oncologists, pulmonologists, and surgeons), NPs, or PAs and currently treating lung cancer patients, as per self-report; * OCP conducts consultations with lung cancer patients, as per self-report; * OCP sees at least 1 lung cancer patient per week, as per self-report; Patient Eligibility * Patient under the care of a participating OCP as per self report; * English and/or Spanish speaking; * In general, which language do you prefer to receive your medical care, English/Spanish/both English and Spanish Equally? * If English, treat as fluent in English, no additional language questions * If Spanish, treat as fluent in Spanish, no additional language questions * If both English and Spanish equally, ask the follow-up questions and go with whichever language is endorsed as best. If endorsed equally, assign to category patient prefers * How well do you speak English? Not at all/ Not well/Well/Very well * How well do you speak Spanish? Not at all/Not well/Well/Very well * Is at least 18 years of age as per self report; * Has a history of suspicious lung mass or confirmed lung cancer diagnosis, as per clinician judgment or medical record note; * Is a former or current smoking as per self report; * Has had no more than 10 prior visits with the participating OCP, as per the medical record and/or self report Exclusion Criteria: Patient Exclusion * Individuals of impaired decision-making capacity as per a clinician's judgment or as documented in the EMR. Site and OCP Exclusion * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advocate Health Care Network

    RECRUITING

    Libertyville, Illinois, 60048, United States

  • BAPTIST ALLIANCE - MCI (Data Collection Only)

    RECRUITING

    Miami, Florida, 33143, United States

  • Chesapeake Regional Healthcare (Data Collection Only)

    RECRUITING

    Chesapeake, Virginia, 23320, United States

  • Fox Chase Cancer Center (Data Collection Only)

    RECRUITING

    Philadelphia, Pennsylvania, 19111, United States

  • Hackensack Meridian Health (Data collection only)

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

  • Munson Healthcare (Data Collection Only)

    COMPLETED

    Traverse City, Michigan, 49684, United States

  • Providence St. Joseph Health (Data Collection Only)

    COMPLETED

    Irvine, California, 92612, United States

  • Roswell Park Cancer Institute (Data Collection Only)

    RECRUITING

    Buffalo, New York, 14263-0001, United States

  • University of Kentucky (Data Collection Only)

    COMPLETED

    Lexington, Kentucky, 40536-0093, United States

  • University of Pennsylvania (Data Collection Only)

    RECRUITING

    Philadelphia, Pennsylvania, 19104-4283, United States

  • Virtua Health (Data Collection Only)

    COMPLETED

    Philadelphia, Pennsylvania, 08060, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.